Latest Steven Nissen Stories
Last week, the American Heart Association ignited a controversy when they released a set of recommendations that suggested 33 million more Americans could benefit from cholesterol-lowering drugs called statins.
A comprehensive study review has added to the growing body of evidence indicating the anti-inflammatory drugs known as statins have no significant side effects.
Federal health authorities are prohibiting new patients from enrolling in a safety study for GlaxoSmithKlineâ€™s controversial diabetes pill Avandia, a week after an expert panel ruled that the drug increases heart risks.
Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio.
Twenty-three million Americans suffer from Type 2 diabetes, and the FDA says it will now strictly screen the drugs created to treat the epidemic.
New findings support the claim that a controversial diabetes pill failed to significantly slow plaque buildup in heart arteries compared with an older drug.
CALGARY, Oct. 7 /PRNewswire-FirstCall/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the formation of the Steering Committee for the RVX-208 Phase 2b clinical trial assessing atherosclerosis by IVUS (Intravascular Ultrasound).
A wrongful death suit was filed against GlaxoSmithKline, SmithKline Beecham, and McKesson Corporation in California Superior Court, charging that Avandia, prescribed for Type 2 Diabetes, led to heart attacks, congestive heart failure and other fatal cardiovascular injuries in seven individuals.
By Matthew Perrone WASHINGTON - Diabetes drugs would be subject to more stringent safety standards that could cost manufacturers millions, under recommendations made Wednesday by a government panel.